See more : Beijing Labtech Instruments Co., Ltd. (688056.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gwo Xi Stem Cell Applied Technology Co. , Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Doms Industries Limited (DOMS.BO) Income Statement Analysis – Financial Results
- JPMorgan Chase & Co. (JPM-PC) Income Statement Analysis – Financial Results
- WPT Industrial Real Estate Investment Trust (WIR-U.TO) Income Statement Analysis – Financial Results
- Allarity Therapeutics, Inc. (ALLR) Income Statement Analysis – Financial Results
- LSI Industries Inc. (LYTS) Income Statement Analysis – Financial Results
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO)
About Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs. The company's products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. It is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 141.18M | 180.67M | 242.75M | 188.54M | 176.68M |
| Cost of Revenue | 44.40M | 25.86M | 45.68M | 21.49M | 55.89M |
| Gross Profit | 96.77M | 154.81M | 197.07M | 167.05M | 120.78M |
| Gross Profit Ratio | 68.55% | 85.69% | 81.18% | 88.60% | 68.36% |
| Research & Development | 108.17M | 109.16M | 95.11M | 86.83M | 93.15M |
| General & Administrative | 68.21M | 88.82M | 69.74M | 63.98M | 81.22M |
| Selling & Marketing | 14.56M | 71.72M | 133.64M | 88.31M | 32.08M |
| SG&A | 82.78M | 160.54M | 203.38M | 152.29M | 110.87M |
| Other Expenses | 0.00 | 6.05M | 4.09M | 3.84M | 0.00 |
| Operating Expenses | 190.73M | 269.70M | 298.49M | 239.12M | 197.96M |
| Cost & Expenses | 235.13M | 295.56M | 344.17M | 260.61M | 253.85M |
| Interest Income | 1.62M | 263.00K | 70.00K | 114.00K | 238.00K |
| Interest Expense | 12.36M | 1.96M | 1.67M | 1.34M | 1.16M |
| Depreciation & Amortization | 58.19M | 59.04M | 34.74M | 26.27M | 16.76M |
| EBITDA | -16.60M | -49.94M | -60.52M | -44.17M | -66.47M |
| EBITDA Ratio | -11.76% | -27.42% | -25.75% | -22.20% | -37.62% |
| Operating Income | -93.96M | -108.58M | -97.26M | -68.12M | -83.23M |
| Operating Income Ratio | -66.55% | -60.10% | -40.07% | -36.13% | -47.11% |
| Total Other Income/Expenses | 6.81M | 3.95M | 326.00K | 292.00K | 5.47M |
| Income Before Tax | -87.15M | -110.94M | -96.94M | -71.78M | -77.76M |
| Income Before Tax Ratio | -61.73% | -61.40% | -39.93% | -38.07% | -44.01% |
| Income Tax Expense | 939.00K | 677.00K | 5.81M | 2.78M | 84.00K |
| Net Income | -88.09M | -112.11M | -105.55M | -84.20M | -76.93M |
| Net Income Ratio | -62.40% | -62.05% | -43.48% | -44.66% | -43.54% |
| EPS | -0.98 | -1.31 | -1.27 | -0.96 | -1.01 |
| EPS Diluted | -0.98 | -1.31 | -1.27 | -0.96 | -1.01 |
| Weighted Avg Shares Out | 89.58M | 85.42M | 82.92M | 87.74M | 76.19M |
| Weighted Avg Shares Out (Dil) | 89.58M | 85.42M | 82.92M | 87.74M | 76.19M |
Source: https://incomestatements.info
Category: Stock Reports